Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on January 8, 2020, covering events occurring on January 9, 2020. The Company, a Delaware corporation, announced the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement, alongside the termination of a prior equity distribution agreement.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction with the following specific metrics:
- Gross Proceeds: Approximately $6.5 million before deducting placement agent fees and offering expenses.
- Securities Issued:
- 1,189,000 shares of Common Stock at $3.9825 per share.
- 448,800 Pre-Funded Warrants at $3.9725 per warrant (exercisable at $0.01 per share).
- Concurrent Warrants: 818,900 warrants issued in a private placement, exercisable at $3.93 per share, expiring 5.5 years from issuance.
- Placement Agent Fee: 6.0% of gross proceeds paid to Maxim Group LLC, plus reimbursement of out-of-pocket expenses (legal fees capped at $50,000).
The filing does not provide current revenue, profit, cash flow, margin, or debt figures, as this is a transactional report rather than a periodic financial statement.
Material Changes and Agreements
The Company executed two primary material changes:
- Entry into Securities Purchase Agreement: The Company agreed to sell the securities described above to certain investors. The transaction includes a 90-day lock-up period restricting the issuance of additional Common Stock or Common Stock Equivalents following the closing.
- Termination of ATM Program: The Company terminated its Equity Distribution Agreement (ATM Program) with Maxim Group LLC, which allowed for the sale of up to $5.0 million in shares. The termination was effective January 9, 2020, with no termination penalties incurred.
Outlook, Risks, and Contingencies
Closing Conditions: The Offerings are expected to close on or about January 13, 2020, subject to customary closing conditions.
Ownership Blockers: Investors are restricted from exercising Pre-Funded Warrants or Warrants if doing so would result in beneficial ownership exceeding 4.99% of outstanding Common Stock. Investors may opt for a 9.99% cap upon issuance or provide 61 days' prior notice to increase ownership up to 9.99%.
Registration Obligations: The Company agreed to use commercially reasonable efforts to file a Form S-1 registration statement for the resale of shares issuable upon warrant exercise within 180 days of closing and to keep it effective.
Risks: The filing notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the actual closing date of the Registered Offering and Private Placement (expected January 13, 2020).
- Confirm the final net proceeds after deducting the 6.0% placement fee and offering expenses.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the filing of the Form S-1 registration statement for warrant shares within the 180-day window.
- Check subsequent filings for any updates regarding the 90-day issuance restriction period.